Scalper1 News
Big-cap biotech Regeneron Pharmaceuticals (REGN) beat Wall Street’s Q1 estimates and raised its guidance Thursday, sending the stock up more than 2% in early trading. Regeneron’s earnings rose 27% over the year-earlier quarter to $2.88 a share, beating analysts’ consensus by 20 cents, according to Thomson Reuters. Revenue climbed 39% to $869.6 million, about $45 million above consensus. The beat came from U.S. sales of Regeneron’s flagship eye Scalper1 News
Scalper1 News